

Chapter 2

Receptor Tyrosine Kinases as Targets for Enhancing Tumor Radiosensitivity

Thomas J. Hayman and Joseph N. Contessa

Abstract The advent of the modern era of molecularly targeted therapies in oncology has generated considerable excitement in the field of oncology. While there have been successes with molecularly targeted agents as monotherapies, most solid tumors display only a transient and modest response to single-targeted agents. As such, there has been significant effort in combining molecularly targeted agents with radiotherapy. Receptor tyrosine kinases (RTKs) play central roles in oncogenesis, stress sensitivity, tumor maintenance/progression, and clinical prognosis. Secondary to these roles, receptor tyrosine kinases are attractive targets for cancer therapy and specifically in combination with radiation therapy to enhance tumor radiosensitivity. Significant preclinical and clinical investigations have been performed to understand their roles in regulating the cellular response to radiation. A number of RTKs with relevance to radiation oncology have been identified including EGFR, VEGFR, IGF-1R, c-MET, and HER2. This chapter will highlight the preclinical and clinical findings associated with the combination of radiotherapy and inhibitors of the aforementioned receptors.

Keywords Radiosensitization • Receptor tyrosine kinase • EGFR • VEGF • c-Met • FGFR • Her2 • Epidermal growth factor receptor • RTK

Introduction

Clinicians have long combined radiation therapy with systemically delivered agents to enhance the local effects of RT, improve tumor control, and enhance patient survival. This combined modality approach couples standard fractionated radiation treatment regimens with cytotoxic chemotherapies such as 5FU, mitomycin, cisplatin,

T.J. Hayman • J.N. Contessa (✉)

Department of Therapeutic Radiology, Yale University School of Medicine,
P.O Box 208040, New Haven, CT, USA

e-mail: Thomas.Hayman@yale.edu; Joseph.Contessa@yale.edu

taxol, and gemcitabine. While these combinations have shown success for specific disease sites in the clinic, substantial limitations exist. Chief among these are the dose limitations and toxicity imposed by normal tissue responses to the nonspecific nature of cytotoxic chemotherapy.

The advent of the modern era of targeted therapies has been met with great excitement in the oncology community. By attacking aberrantly activated pathways only present in tumor cells, targeted therapies have the potential benefit of being able to minimize normal tissue toxicity while maximizing tumor effect. While there have been successes with the use of targeted agents as monotherapies (e.g., imatinib in the BCR-Abl-driven chronic myeloid leukemia) [1], most common solid tumors have shown only a modest and transient response to single-targeted agents [2]. As such, tremendous effort has been expended in studying the combinations of these molecularly targeted agents with standard chemotherapies and/or radiation.

One target-rich area of tumor biology that has received considerable interest is membrane receptor (or specifically receptor tyrosine kinase) signaling. These kinases have been shown to play an important role in oncogenesis, stress sensitivity, tumor maintenance/progression, and clinical prognosis [3]. Secondary to these roles, receptor tyrosine kinases (RTKs) are attractive targets for cancer therapy and specifically in combination with radiation therapy to tumor radiosensitivity. As such, considerable preclinical and clinical investigations have been performed to understand their roles in regulating the cellular response to radiation. A number of RTKs with relevance to radiation oncology have been identified including EGFR, VEGFR, IGF-1R, c-MET, and HER2 [2, 4, 5]. This chapter will highlight the substantial preclinical and clinical findings associated with the combination of radiotherapy and inhibitors of the aforementioned receptors.

EGFR

The erbB family of receptors has been the subject of extensive laboratory and clinical investigations. The erbB family consists of four distinct receptors: EGFR (erbB1), HER-2/NEU (erbB2), erbB3, and erbB4 [6]. EGFR or epidermal growth factor receptor is the most well studied of the family with regard to its role in modulating a tumor's response to radiation.

The EGFR is a 170-kDa transmembrane RTK that plays an important role in carcinogenesis, tumor progression, and response to therapy [6]. Structurally, EGFR is comprised of four extracellular domains, a hydrophobic transmembrane domain, a juxtamembrane sub-domain, an intracellular tyrosine kinase domain, and c-terminal phosphorylation sites [6]. The natural ligands of the EGFR include epidermal growth factor (EGF), transforming growth factor alpha (TGF- α), epiregulin, betacellulin, amphiregulin, and heparin-binding EGF-like growth factor (HB-EGF) [7]. The EGFR is present in a monomeric state, but ligand binding drives a conformational change of the extracellular domain that causes receptor

homo- and heterodimerization with other ErbB family receptors [8]. This dimerization activates intracellular tyrosine kinase domain auto- and transphosphorylation and initiates downstream signal transduction [8]. The EGFR and other RTKs are also activated by ionizing radiation [9]. The mechanisms that underlie this phenomenon include (1) receptor clustering and dimerization [10, 11], (2) radiation-induced release of autocrine ligands [12], and (3) phosphatase inactivation [13].

Signal transduction downstream of the EGFR occurs through a number of critical pathways including RAS/RAF/MAPK, PI3K/AKT/mTOR, Jak/STAT, Src, and PLC-DAG/PKC [14–18]. While the goal of this chapter is not to describe in detail each of these pathways, it is important to highlight their respective roles in the radiation response and tumor biology in general. The PI3K/AKT/mTOR pathway has been shown to be directly involved in regulating cell survival after radiation both *in vitro* and *in vivo* [19–21]. Various investigations have demonstrated different mechanisms by which this pathway governs radiosensitivity: through regulation of metabolic demands through activation of the mechanistic target of rapamycin (mTOR) kinase, control of proliferative signaling via MAPK cascade stimulation, and activation of cell survival signaling through AKT [22]. Other work has also documented the roles of Jak/STAT and PKC pathways in influencing tumor cell radiosensitivity [23, 24]. Ultimately activation of these pathways modifies cellular responses and repair programs induced by DNA damage, and regulation of these critical oncogenic pathways by EGFR underscores its potential as a target for enhancing tumor radiosensitivity and improving patient outcomes.

EGFR has a well-documented role in cancer [6] that was initially implicated by increased expression levels in a wide range of cancers including ovarian, brain, breast, colorectal, non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinomas (HNSCC) [25, 26]. Based upon this appreciation, several classes of EGFR inhibitors have been developed. These inhibitors belong broadly to two classes: monoclonal antibodies (mAb) that target the extracellular ligand-binding domain and small molecule inhibitors that target the intracellular kinase domain [2, 27]. mAbs to the EGFR recognize, inactivate, and remove the receptor from the cell surface, and several mAbs have been advanced to the clinic including cetuximab, panitumumab, and matuzumab [2, 27]. Cetuximab is FDA approved for the treatment of HNSCC in combination with radiation [2, 5, 27]. Small-molecule tyrosine kinase inhibitors (TKIs), which bind to the intracellular ATP-binding domain of the EGFR, prevent receptor phosphorylation and subsequent signal transduction [2, 27]. A number of these TKIs have been developed and tested in the laboratory and clinic. Gefitinib and erlotinib are two EGFR-specific TKIs developed as single agents for advanced NSCLC and that have demonstrated efficacy in clinical trials [28, 29].

The observation that prolonged exposure of head and neck cancer cells to EGF enhanced the effects of radiation by clonogenic survival began to spark interest in studying the effects of EGFR modulation and radiation [30, 31]. While these initial *in vitro* results seem counterintuitive, it is likely that prolonged EGF exposure resulted in EGFR internalization and degradation causing a decrease in EGFR signaling. Another early study by Balaban et al. showed that targeting of

EGFR via the anti-EGFR antibody LA22 resulted in an increase in radiation-induced apoptosis [32]. Additionally, several other groups demonstrated in pre-clinical models (in vitro and in vivo) that EGFR expression inversely correlated with radiation sensitivity [33–35]. This correlation was also observed in clinical samples, and in fact poor survival of HNSCC patients with high EGFR tumors was shown to be secondary to poorer local regional tumor control and not distant metastasis [36]. The in vitro observation that radiation activates EGFR receptor phosphorylation [9, 37] and several downstream signaling cascades such as Ras/MAPK and PI3K/AKT/mTOR [17, 38] provided a mechanistic rationale for targeting EGFR function concurrent with RT, and genetic models of EGFR blockade indeed provided evidence that radiosensitization could be achieved through EGFR inhibition [10, 39].

These initial preclinical results, as well as parallel work examining EGFR targeting as a monotherapy, led to the development of the mAb, C225 (now known as cetuximab). C225 was shown to enhance radiation effects in vitro in HNSCC cell lines despite also causing a G1 cell cycle arrest, a finding that supported the potential for clinical translation [40]. Preclinical and clinical research has also been performed on additional mAbs such as mAb806, which recognizes an activation-specific conformation of the receptor. This antibody has been shown to bind a cryptic EGFR epitope that is exposed in the presence of oncogenic mutations such as EGFRvIII or is coincident with overexpression and activation of wild-type EGFR [41]. The specificity of blocking activated EGFR signaling in tumor cells with this Mab represents an intriguing strategy to minimize normal tissue toxicity [41]. Phase I clinical trial testing with mAB806 (ABT806) has been completed in patients with advanced solid malignancies (NCT01255657) although results have not yet been reported [42].

Preclinical studies have also investigated combinations of radiation and mAbs or TKIs that target EGFR in NSCLC, breast adenocarcinoma, and glioblastoma [40, 43–45]. Effects on in vitro intrinsic radiosensitivity as determined by clonogenic survival assays have been modest but consistent in most instances [2]. In vivo results from the combination of radiation and EGFR inhibition have typically been more striking with concurrent treatment, resulting in greater than additive effects on tumor growth delay [2]. In vivo radiosensitization has been achieved with both single fractions of radiation as well as the more clinically relevant fractionated radiation schedules [7, 46]. For example, treatment of tumor xenografts with gefitinib [47, 48] in combination with radiation resulted in inhibition of tumor growth that was greater than either modality alone. The discrepancy between in vitro and in vivo results has been hypothesized to be related to several different mechanisms that would only be apparent in vivo including inhibition of angiogenesis and reduction in tumor cell invasion [2].

Secondary to the promising preclinical results in the aforementioned paragraphs, numerous clinical trials have been designed evaluating the efficacy of combining EGFR inhibitors with radiation [49]. Perhaps the most notable of these trials was a phase III multicentered randomized controlled trial with 424 patients

with locoregionally advanced HNSCC [50]. The trial compared treatment with radiotherapy alone to radiotherapy plus cetuximab. The results were striking and showed an increase in overall survival (OS) from 29.3 months with radiotherapy alone to 49.0 months with the combination of radiotherapy and cetuximab (hazard ratio for death 0.73; $P=0.03$). Local control rates were also significantly improved with the addition of cetuximab to radiotherapy (50 % vs. 41 % in the radiotherapy alone arm).

Building upon the Bonner et al. study, RTOG 0522 was designed to answer the question as to whether the addition of cetuximab to cisplatin-based standard chemoradiotherapy (CRT) improved outcomes [51]. This phase III clinical trial randomized patients to concurrent CRT (cisplatin+radiotherapy) alone or with cetuximab in patients with stage III/IV HNSCC. The results of the study showed no difference in OS or PFS with the addition of cetuximab to standard cisplatin-based CRT. However the critical unanswered question is whether cetuximab could replace cisplatin as a radiosensitizing agent for definitive CRT of locoregionally advanced HNSCC. RTOG 1016 was designed to answer this question in a subset of HPV-positive HNSCC [42] and randomizes patients with oropharyngeal cancer to CRT with cisplatin or cetuximab. This trial began recruiting in 2011 and outcomes are pending.

The combined results of the Bonner et al. trials, the preclinical data suggesting that EGFR is a target for radiosensitization, and data showing that the majority of NSCLCs overexpress EGFR led to the development of a 2×2 phase III trial in NSCLC evaluating the use of cetuximab and radiation dose escalation up to 74 Gy [52]. The results of this study, however, were disappointing and showed that addition of cetuximab to chemoradiotherapy in patients with locally advanced NSCLC did not affect patient survival. Why did cetuximab fail to radiosensitize NSCLC? The most likely explanation is that the radiosensitizing effect of EGFR inhibition was not additive with chemotherapy. Alternative explanations include the possibility that tumors from this primary site either contain parallel signaling mechanisms that compensate for EGFR inhibition or that EGFR is not a primary driver of cell survival.

The results of the RTOG 0617 and other negative clinical trials combining EGFR targeting with radiation/chemotherapies raise several important questions about how to advance this treatment strategy. The most important of these is how patients that respond to EGFR inhibition in combination with radiation can best be identified prior to treatment. This concept is currently undergoing extensive evaluations in both the laboratory and the clinic [2]. For example, it has been suggested that p16+ HNSCC are more sensitive to the combination of cetuximab and radiation [53]. In contrast, and somewhat surprisingly, EGFR expression has not shown to correlate to response to combination chemotherapy and cetuximab [54]. In fact responses to EGFR inhibition have been shown with a lack of EGFR staining by immunohistochemistry (IHC) [55], confirming that identification of mechanistic biomarkers will be valuable for directing future approaches for EGFR targeting and radiosensitization.

VEGF/VEGFR

Angiogenesis is a hallmark of tumor progression and metastasis, and the VEGF growth factor and its receptors play critical roles in the regulation of angiogenesis [56]. The VEGF family of proteins consists of VEGF A–E and placenta growth factor (PLGF) 1–2. VEGFA is the most abundant of the VEGF proteins and exerts its effects primarily by binding to VEGFR-1 and VEGFR-2 [56, 57]. Like the EGFR, both transmembrane RTKs are stimulated by ligands and undergo dimerization, autophosphorylation of its intracellular tyrosine residues, and initiation of downstream signaling [56]. These receptors exist primarily on vascular endothelial cells [56, 57]. VEGFR-1 is thought to be involved in vascular system development during angiogenesis, whereas VEGFR-2 is the primary mediator of the angiogenic, mitogenic, and vascular permeability-enhancing effects of VEGF. VEGFR-2 signals downstream via PI3K/AKT/mTOR and the RAS/MAPK pathways to enhance endothelial cell proliferation and survival [57].

VEGF is overexpressed in many solid tumors [57]. This increased expression has been shown to correlate with worse PFS and OS [56, 58]. As such anti-VEGF therapy has garnered significant interest as a cancer therapy, and development of bevacizumab, a humanized monoclonal antibody, is directed against VEGF that prevents its binding to VEGFR-1 and VEGFR-2 [59].

It was initially thought that antiangiogenic therapy would impair the effects of ionizing radiation by the induction of tumor hypoxia, as oxygen is thought to be critical to the formation of free radicals that cause DNA double-strand breaks and cell death [60]. However, early studies by Teicher et al. showed that this might not be true for all tumors as antiangiogenic therapy with the angiogenesis inhibitor TNP-470 and minocycline actually improved tumor oxygenation and the antitumor effects of radiotherapy [61]. Furthermore the interaction with EGFR signaling, which potentiates production of VEGF [62], suggests that enhanced angiogenesis is a mechanism for both tumor and vessel radioresistance [62]. Because of the increase in oxygenation with antiangiogenic therapies and data showing enhancement of VEGF levels by RT, it was postulated that strategies targeting angiogenesis might augment the radiation response.

In the first preclinical study of a targeted antiangiogenic therapy with radiation, it was shown that angiostatin, a natural product that inhibits angiogenesis, enhanced the effects of radiation on *in vivo* murine lung cancers as well as human glioblastoma, squamous cell carcinoma, and prostate carcinoma xenografts [63]. Gorski et al. showed that anti-VEGF antibodies in combination with radiation (20 and 40 Gy) in several tumor xenografts (lung carcinoma, squamous cell carcinoma, glioblastoma, and esophageal carcinoma) caused a greater than additive increase in tumor growth delay than either therapy alone [64]. DC101 an inhibitor of mouse VEGFR-2 has also been used in several preclinical studies to enhance the effects of radiation [65]. Kozin et al. showed that the use of DC101 before, during, and after fractionated radiation therapy decreased the dose of radiation required to control 50% of tumors locally in 54a (lung carcinoma) and U87 (glioma) xenografts by 1.7- and 1.3-fold, respectively [66].

Several potential mechanisms have been described with regard to anti-VEGF therapies and increased response to radiation. First, it has been suggested that anti-VEGF therapy increases the radiosensitivity of vascular endothelial cells [64]. Several studies have shown increased apoptosis of vascular endothelial cells with anti-VEGF therapy and radiation [65, 66]. The increased death of endothelial cells then can reduce vascular density and inhibit the formation of new blood vessels causing impaired nutrient delivery to the tumor [65]. Secondly, studies have shown that anti-VEGF agents can renormalize the vasculature causing an increase in tumor oxygenation and hence an increase in tumor radiosensitivity [67, 68].

Secondary to the promising preclinical findings mentioned above, clinical trials have been performed with anti-VEGF therapy both as monotherapy and in combination with radiation. Several phase I/II clinical trials have been published showing promising results in many tumor types (e.g., glioblastoma, rectal cancer, and HNSCC) [69]. These early clinical trials in patients with glioblastoma led to the development of two phase III clinical trials. The RTOG 0825 was a phase III double-blind randomized controlled trial comparing conventional concurrent chemoradiation and adjuvant temozolomide plus bevacizumab vs. conventional concurrent chemoradiation and adjuvant temozolomide in patients with newly diagnosed glioblastoma [70]. The data showed that there was no increase in OS with the addition of bevacizumab to standard therapy even though there was a trend toward increased PFS (HR, 0.79; 95 % CI, 0.66 to 0.94; $P=0.007$). A similar study, AVAglio (Avastin in glioblastoma), was a phase III study that evaluated the efficacy of adding Avastin (bevacizumab) to standard chemoradiation and adjuvant temozolomide in patients with newly diagnosed glioblastoma [71]. After surgery or biopsy, patients were randomized to receive concurrent radiation and temozolomide plus either Avastin or placebo. After the completion of six cycles of maintenance temozolomide and Avastin or placebo, the patients continued on Avastin or placebo until disease progression or unacceptable side effects are presented. OS was nearly identical between the two arms. The improvement in PFS (10.6 months with Avastin vs. 6.2 months with placebo; HR 0.64; 95 % CI, 0.55–0.74; $P<0.001$) observed in this study reflects the drug's clinical effectiveness for targeting angiogenesis without enhancing the radiosensitivity of glioblastoma tumor cells.

The disappointing results of these clinical trials in GBM suggest that the rationale for radiosensitization must be reevaluated. Chief among these concerns is the hypothesis that VEGFR inhibition does not increase hypoxia in human tumors as this effect could counteract the combination of antiangiogenic therapy with radiation. Additionally biomarkers and patient selection may also provide a way to identify patients most likely to benefit from anti-VEGF agents. We also know from preclinical results that treatment combinations with anti-VEGF agents and radiation are treatment dose dependent [72]. This emphasizes careful consideration and understanding of the clinical design of combinations of radiation and anti-VEGF agents. In addition, similar to anti-EGFR agents, patients being treated with anti-VEGF/VEGFR agents experience resistance to therapy [72]. In patients with glioblastoma who experienced clinical progression on cediranib (a potent TKI of VEGFRs), significant increases in plasma bFGF and stromal cell-derived growth factor (SDF1a)

were noted [73]. This is in agreement with preclinical models where cross talk between many angiogenic factors including VEGF, PDGF, angiopoietins, ephrin, and Notch has been shown [56, 74]. Thus although inhibition of a single factor may not be sufficient to fully inhibit angiogenesis in all patients, study of rationale combinations of anti-VEGF therapy with other targeted agents in preclinical models may provide valuable insights for combining RT with targeting of angiogenesis.

c-Met

c-Met, also known as the hepatocyte growth factor (HGF) receptor, is a 170-KD transmembrane receptor tyrosine kinase that plays an important role in tumorigenesis and metastasis [75]. Like other RTKs, ligand binding activated receptor activity through dimerization and phosphorylation of intracellular tyrosine kinase domains [76]. Downstream signaling occurs through many of the previously mentioned oncogenic signaling pathways including PI3K/AKT/mTOR, RAS/MAPK, and JAK/STAT [77, 78].

HGF was originally identified as a cytokine that caused the dissociation of colonies of cells into single cells [79] and is a pro-migratory ligand that accumulates in the extracellular matrix and is linked to tumor cell invasion. HGF also promotes epithelial-mesenchymal transition (EMT) [79–82], which in turn causes further increases in tumor cell migration, invasion, and angiogenesis [77].

HGF/c-MET autocrine ligand signaling is aberrantly activated in a number of different cancers including breast, glioma, NSCLC, SCLC, and colon cancer [83–88]. Increased production of HGF by both cancer cells and the surrounding stroma as well as gene amplification and overexpression of c-Met has been described as mechanisms for activating this autocrine loop. Increased production/upregulation of the HGF/c-Met axis has also been shown to be a negative prognostic indicator [77, 89, 90]. For example, increased expression of HGF and c-Met in colon cancer is associated with worse disease stage [91], lymph node metastasis [91], and decreases in PFS and OS [86].

c-Met activation and signaling has been linked to resistance to both DNA-damaging chemotherapies and ionizing radiation [77]. One of the earliest studies to link HGF/c-Met and resistance to DNA-damaging therapies was done by Fan et al. [92]. This study showed that pretreating breast cancer cells with HGF decreased DNA fragmentation induced by DNA-damaging agents. In a further study, they showed this effect to be mediated by c-Met through the PI3K/AKT pathway [93]. In clinical studies increased c-Met expression has been shown to be an independent predictor of local failure in patients undergoing definitive radiation for SCC of the oropharynx [94].

Preclinical studies have explored the relationship between radiation and c-Met signaling. De Bacco et al. showed that irradiation induced c-Met expression in a variety of cell lines [95]. Furthermore they found that inhibition of c-Met activity with the small molecule tyrosine kinase inhibitors PHA665752 (or JNJ-38877605)

sensitized glioma and breast cancer cells to irradiation in vitro and in tumor xenograft model systems [95]. Increased c-Met expression/activation after radiation has been reported in pancreatic cancer, glioblastoma, and neuroblastoma model systems [96–98], and Chu et al. reported that in glioblastoma cells, radiation-induced HGF secretion leads to activation of c-Met signaling in glioma cell lines [97].

Based upon the above observations several groups have begun to define the role of HGF/c-Met in mediating cell survival after exposure to ionizing radiation. Welsh et al. showed that inhibition of c-Met with siRNA and the small molecule inhibitor MP470 can radiosensitize glioma cells to radiation in vitro and in vivo [99]. In these studies, radiation-induced DNA damage repair via a decrease in Rad51 expression after irradiation was implicated as the mechanism for radiosensitization. In gastric carcinoma cells, inhibition of c-Met was shown to decrease phosphorylation of ATR and checkpoint kinase 1 (CHK1) [100]. Similar results demonstrating radiosensitization have been shown in other glioblastoma xenograft models as well as in vitro and in vivo models of prostate cancer, thyroid cancer, and NSCLC [101–105].

A number of different inhibitors of the HGF/c-Met signaling axis are available for clinical use [77, 106]. These include anti-HGF antibodies (ficlatuzumab, rilotumumab, and TAK-701), anti-Met antibodies (onartuzumab), and small molecule tyrosine kinase inhibitors (cabozantinib, foretinib, and tivantinib). Several of these molecules have been combined with other targeted agents including anti-EGFR inhibitors [77].

To date only one clinical trial of radiation and c-Met inhibition has been performed. This was a phase 1 safety trial of cabozantinib with temozolomide and radiation in newly diagnosed glioblastoma patients. The study closed in 2013 and the results have not been reported at the time of this publication [42]. Given the aforementioned preclinical and clinical data, it is logical to further explore the combination of radiation and c-Met inhibition with the goal of testing whether inhibition of Met signaling can enhance the effects of radiation therapy in malignant tumors.

Other RTKs

There are several other RTKs that have been studied with regard to their role in the radioresponse, however, to a lesser degree than the previously described receptors. One such studied RTK is the insulin-like growth factor-type 1 receptor (IGF-1R). The IGF family proteins are the primary ligand for IGF-1R [107]. Their binding acts similarly to the other RTKs discussed above [108]. IGF-1R signaling has been linked to malignant transformation, cellular proliferation, cell survival and differentiation [109], as well as increased local recurrence after RT [110].

With regard to regulation of the radiation response, several preclinical studies have been performed showing radiosensitization both in vitro and in vivo. Riesterer et al. showed that the use of A12, an anti-IGF-1R antibody, caused radiosensitization of HNSCC cell lines in vitro via the clonogenic survival assay as well as in vivo

as measured by tumor growth delay [111]. Allen et al. published similar results with the combination of A12 and radiation in H226 lung cancer xenografts [112]. Recent data by Chitnis et al. reports IGF-1R inhibition by AZ12253801, a selective IGF-1R tyrosine kinase inhibitor that radiosensitizes tumor cell lines via an inhibition of both HR and NHEJ [113].

More recently several studies have begun to define the use of IGF-1R inhibitors in combination with radiation and EGFR blockade. The rationale for these studies lies in data showing cross talk between the EGFR and IGF-1R pathways at multiple levels [114, 115]. In fact, EGFR inhibition has been shown to cause increased response to IGF-1R ligands [114, 115]. Li et al. demonstrated that co-inhibition of EGFR and IGF-1R using specific small molecule tyrosine kinase inhibitors to both receptors caused synergistic radiosensitization in breast cancer cell in vitro and in tumor xenografts [116].

HER2 (or erbB2) is an RTK that has no known soluble ligand. However, it exerts its actions by formation of heterodimers with the other ErbB family members, notably EGFR. HER2 overexpression has been noted in approximately 30% of breast cancers [117] and 20% of gastroesophageal (GE) and gastric cancers [118]. Trastuzumab, a monoclonal antibody to the external domain of HER2, has been approved for clinical use in metastatic breast cancer and shows activity in preclinical models as well [119]. With regard to the role of HER2 in regulating radiosensitivity, much less is known, with only a few reports combining radiation with specific anti-HER2 therapies. One such study by Pietras et al. showed that trastuzumab treatment radiosensitized the breast cancer cell line MCF7 in vitro and in tumor xenografts only under conditions of HER2 overexpression [120]. Instead, most studies examining the role of Her2 in the radiation response have focused on the use of lapatinib a dual EGFR and Her2 inhibitor. Using lapatinib, several groups have shown an increase in radiosensitivity [121–123]. For example, Sambade et.al demonstrated that the effects of lapatinib plus radiation on tumor growth of HER2+/EGFR+ breast cancer xenografts were greater than additive of either therapy alone [121].

Although there is a paucity of preclinical data with regard to the combination of radiation and anti-HER2 therapies, there have been several clinical trials completed combining the two treatments. The Brown University Oncology Group performed a pilot study of trastuzumab in addition to chemoradiation in patients with HER2+ locally advanced esophageal adenocarcinoma [124]. Despite the patients' advanced burden of disease, a 3-year OS of 47% was observed with no increase in adverse events. This study led to the development of RTOG 1010 in which patients with HER2+ locally advanced esophageal adenocarcinoma and GE junction tumors are randomized to chemoradiation plus concurrent and maintenance trastuzumab or chemoradiation [119]. This trial is still open to accrual [42]. In breast cancer, several large clinical trials including the NSABP B-31 and NCCTG N9831 trials have been completed [42]. These trials have compared the addition of trastuzumab to chemotherapy in node-positive or high-risk node-negative nonmetastatic, operable breast cancer patients [125]. Approximately 70% of patients in both studies underwent adjuvant radiotherapy concurrently with trastuzumab. DFS ($P < 0.001$; stratified HR, 0.52; 95% CI, 0.45 to 0.60) and OS ($P < 0.001$; stratified HR, 0.61; 95% CI,

0.50–0.75) were significantly increased with the addition of trastuzumab. While this study was not directly comparing the effect of adding trastuzumab to adjuvant radiotherapy, some of the effects seen may have been due to this addition.

The fibroblast growth factor (FGF) pathway has also been studied with regard to its role in regulation of the cellular response to radiation. The FGFs mediate their biological effects through the FGF receptors (FGFRs). The four known FGFRs include FGFR-1, FGFR-2, FGFR-3, and FGFR-4 [125, 126]. Their activation is controlled by a unique combination of ligand (FGFs) binding as well as heparin sulfate glycosaminoglycan cofactors [127]. The FGF/FGFR signaling axis has a well-documented role in cancer [126]. Activating mutations, receptor overexpression, and alternative splicing have been shown to augment tumorigenesis in a variety of malignancies [126, 128–132]. Expression of FGFR-1 is a known predictor of poor overall survival and shorter time to progression in patients with glioblastoma [132, 133].

Several early reports began to define the role of the FGF/FGFR axis in regulating cellular survival after radiation [130, 133–135]. Fuks et al. showed that basal FGF (bFGF or FGF2) protected endothelial cell from radiation-induced apoptosis and that administration of bFGF to mice protected against the development of fatal radiation pneumonitis [134]. Other studies showed that expression of FGF2 in human tumor cell lines led to an increase in their relative radioresistance via the small GTPase RhoB [136]. A recent study by Ader et al. used an allosteric FGFR small molecule inhibitor, SSR128129E, to determine the effects of FGFR inhibition on glioma cell radiosensitivity [137]. They showed that inhibition of FGFR signaling enhanced in vitro radiosensitivity of two glioma cell lines via the clonogenic survival assay. Additionally the combination of radiation and SSR128129E significantly enhanced neurologic sign-free survival of mice bearing orthotopic glioma xenografts. Furthermore, Cazet et al. showed that disruption of glycosylation via inhibition of mannose phosphate isomerase inhibited FGFR signaling and enhanced radiosensitivity of glioma cell lines in vitro [133]. The preclinical results are promising and suggest further investigation into the role of FGF/FGFR signaling in regulating the cellular radioresponse both preclinically and clinically.

Conclusion

Significant progress has been made toward the understanding of receptor tyrosine kinase signaling in radiotherapy. The extensive body of literature reviewed above with regard to EGFR, VEGF/VEGFR, c-MET, IGF-1R, and HER2 illustrates this progress. These findings underscore the importance of the rational translation of preclinical data to the clinical setting. Perhaps the best example of this success is shown by the Bonner et al. showing substantial overall survival benefit with the addition of cetuximab to radiation therapy in HNSCC patients [50].

These successes in the preclinical and clinical settings are not without their limitation. First of all, resistance to these therapies is common [27, 119, 138]. As discussed above, the mechanisms of resistance are complicated and can possibly vary from

tumor to tumor, and thus we are only beginning to understand the mechanisms of resistance. This understanding will allow us to pursue logical combinations of targeted agents in combinations with radiotherapy both preclinically and clinically. Secondly, it appears that with many of the agents that target RTKs, only a subset of tumors actually responds to a given therapy. This fact underscores the importance of being able to prospectively select patients for a given therapy. As illustrated above, this work has begun but has proved to be challenging and will require further investigation. Thirdly, in many of the clinical trials with agents targeting RTK pathways, there was a lack of true target engagement [2]. Being able to determine whether an agent is clearly inhibiting its target in the tumor and actually having an effect on downstream signaling is paramount to being able to judge success or failure in the clinic. While this may be challenging, it is of utmost importance to ensure proper interpretation of results.

Importantly an understanding of which molecular subtypes of tumors will respond to the combination of radiation and RTK inhibition will be of considerable significance. This has been an area of considerable interest with regard to inhibitors of RTKs as monotherapies [2, 27]. For instance, in lung carcinoma, it has been demonstrated that tumors that harbor KRAS mutations are resistant to EGFR inhibition [139]. Similarly PTEN deletion in glioblastoma patients causes resistance to EGFR-directed therapeutics. As both KRAS mutations and PTEN cause activation of signaling downstream of RTKs, it is rational to expect these mutations to confer resistance to inhibitors upstream molecules. A recent study by Bennett et al. extended these results to the combination of radiation and inhibition of RTK signaling via aclacinomycin (Acm) treatment [140]. They demonstrated that Acm was only effective as a radiosensitizer when used on cell lines that were EGFR dependent but not on cell lines that harbored KRAS mutations (EGFR independent) [141]. These results underscore the importance of choosing tumors with molecular characteristics that will be expected to respond to RTK-targeted therapies. As such future studies aimed at determining molecular signatures of responsive tumors will bear relevance to molecular radiation oncology.

While the mechanism of action of how these agents interact with radiation is beginning to be elucidated, much has yet to be learned. A mechanistic understanding of this interaction will allow for differing treatment schedules and rationale combinations with other therapies. Additionally, understanding the mechanisms of radiosensitization may allow us to exploit certain tumors based upon their specific genotypes or pathway alterations. As such continued investigation into all of the above RTKs should continue to provide a wealth of knowledge that will ultimately be able to benefit patients with many different types of tumors.

References

1. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. *N Engl J Med* 344(14):1038–1042. doi:[10.1056/NEJM200104053441402](https://doi.org/10.1056/NEJM200104053441402)

2. Nyati MK, Morgan MA, Feng FY, Lawrence TS (2006) Integration of EGFR inhibitors with radiochemotherapy. *Nat Rev Cancer* 6(11):876–885. doi:[10.1038/nrc1953](https://doi.org/10.1038/nrc1953)
3. Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. *Nat Rev Cancer* 4(5):361–370. doi:[10.1038/nrc1360](https://doi.org/10.1038/nrc1360)
4. Kim DW, Huamani J, Fu A, Hallahan DE (2006) Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. *Int J Radiat Oncol Biol Phys* 64(1):38–46. doi:[10.1016/j.ijrobp.2005.02.008](https://doi.org/10.1016/j.ijrobp.2005.02.008)
5. Meyn RE, Munshi A, Haymach JV, Milas L, Ang KK (2009) Receptor signaling as a regulatory mechanism of DNA repair. *Radiother Oncol* 92(3):316–322. doi:[10.1016/j.radonc.2009.06.031](https://doi.org/10.1016/j.radonc.2009.06.031)
6. Herbst RS (2004) Review of epidermal growth factor receptor biology. *Int J Radiat Oncol Biol Phys* 59(2 Suppl):21–26. doi:[10.1016/j.ijrobp.2003.11.041](https://doi.org/10.1016/j.ijrobp.2003.11.041)
7. Zips D, Krause M, Yaromina A, Dorfner A, Eicheler W, Schütze C, Gurtner K, Baumann M (2008) Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results. *J Pharm Pharmacol* 60(8):1019–1028. doi:[10.1211/jpp.60.8.0008](https://doi.org/10.1211/jpp.60.8.0008)
8. Überall I, Kolar Z, Trojanec R, Berkovcova J, Hajdich M (2008) The status and role of ErbB receptors in human cancer. *Exp Mol Pathol* 84(2):79–89. doi:[10.1016/j.yexmp.2007.12.002](https://doi.org/10.1016/j.yexmp.2007.12.002)
9. Schmidt-Ullrich RK, Valerie K, Fogleman PB, Walters J (1996) Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. *Radiat Res* 145(1):81–85
10. Contessa JN, Reardon DB, Todd D, Dent P, Mikkelsen RB, Valerie K, Bowers GD, Schmidt-Ullrich RK (1999) The inducible expression of dominant-negative epidermal growth factor receptor-CD53 results in radiosensitization of human mammary carcinoma cells. *Clin Cancer Res* 5(2):405–411
11. Li W, Li F, Huang Q, Frederick B, Bao S, Li CY (2008) Noninvasive imaging and quantification of epidermal growth factor receptor kinase activation in vivo. *Cancer Res* 68(13):4990–4997. doi:[10.1158/0008-5472.CAN-07-5984](https://doi.org/10.1158/0008-5472.CAN-07-5984)
12. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, Schmidt-Ullrich R (1999) Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. *Mol Biol Cell* 10(8):2493–2506
13. Sturla LM, Amorino G, Alexander MS, Mikkelsen RB, Valerie K, Schmidt-Ullrich RK (2005) Requirement of Tyr-992 and Tyr-1173 in phosphorylation of the epidermal growth factor receptor by ionizing radiation and modulation by SHP2. *J Biol Chem* 280(15):14597–14604. doi:[10.1074/jbc.M413287200](https://doi.org/10.1074/jbc.M413287200)
14. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. *Nat Rev Drug Discov* 4(12):988–1004. doi:[10.1038/nrd1902](https://doi.org/10.1038/nrd1902)
15. Irwin ME, Bohin N, Boerner JL (2011) Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells. *Cancer Biol Ther* 12(8):718–726. doi:[10.4161/cbt.12.8.16907](https://doi.org/10.4161/cbt.12.8.16907)
16. Oliva JL, Griner EM, Kazanietz MG (2005) PKC isozymes and diacylglycerol-regulated proteins as effectors of growth factor receptors. *Growth Factors* 23(4):245–252. doi:[10.1080/08977190500366043](https://doi.org/10.1080/08977190500366043)
17. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD, Contessa JN, Rorrer WK, Chen PB (1997) Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. *Oncogene* 15(10):1191–1197. doi:[10.1038/sj.onc.1201275](https://doi.org/10.1038/sj.onc.1201275)
18. Sebolt-Leopold JS, Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. *Nat Rev Cancer* 4(12):937–947. doi:[10.1038/nrc1503](https://doi.org/10.1038/nrc1503)
19. Chen DJ, Nirodi CS (2007) The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. *Clin Cancer Res* 13(22 Pt 1):6555–6560. doi:[10.1158/1078-0432.CCR-07-1610](https://doi.org/10.1158/1078-0432.CCR-07-1610)
20. Hayman TJ, Kramp T, Kahn J, Jamal M, Camphausen K, Tofilon PJ (2013) Competitive but not allosteric mTOR kinase inhibition enhances tumor cell radiosensitivity. *Transl Oncol* 6(3):355–362

21. Hayman TJ, Wahba A, Rath BH, Bae H, Kramp T, Shankavaram UT, Camphausen K, Tofilon PJ (2014) The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells. *Clin Cancer Res* 20(1):110–119. doi:[10.1158/1078-0432.CCR-13-2136](https://doi.org/10.1158/1078-0432.CCR-13-2136)
22. Toulany M, Rodemann HP (2010) Membrane receptor signaling and control of DNA repair after exposure to ionizing radiation. *Nuklearmed Nucl Med* 49(Suppl 1):S26–S30
23. Bonner JA, Trummell HQ, Willey CD, Plants BA, Raisch KP (2009) Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma. *Radiother Oncol* 92(3):339–344. doi:[10.1016/j.radonc.2009.06.022](https://doi.org/10.1016/j.radonc.2009.06.022)
24. Willey CD, Xiao D, Tu T, Kim KW, Moretti L, Niermann KJ, Tawtawy MN, Quarles CC, Lu B (2010) Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances anti-angiogenic effect of radiation. *Int J Radiat Oncol Biol Phys* 77(5):1518–1526. doi:[10.1016/j.ijrobp.2009.06.044](https://doi.org/10.1016/j.ijrobp.2009.06.044)
25. Mendelsohn J (2001) The epidermal growth factor receptor as a target for cancer therapy. *Endocr Relat Cancer* 8(1):3–9
26. Ruddle J, Wennekes VE, Meissner W, Werner JA, Mandic R (2010) EGF-dependent induction of BCL-xL and p21CIP1/WAF1 is highly variable in HNSCC cells—implications for EGFR-targeted therapies. *Anticancer Res* 30(11):4579–4585
27. Cohen RB (2014) Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). *Cancer Treat Rev* 40(4):567–577. doi:[10.1016/j.crv.2013.10.002](https://doi.org/10.1016/j.crv.2013.10.002)
28. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. *JAMA* 290(16):2149–2158. doi:[10.1001/jama.290.16.2149](https://doi.org/10.1001/jama.290.16.2149)
29. Ellis PM, Coakley N, Feld R, Kuruvilla S, Ung YC (2015) Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. *Curr Oncol* 22(3):e183–e215. doi:[10.3747/co.22.2566](https://doi.org/10.3747/co.22.2566)
30. Kwok TT, Sutherland RM (1989) Enhancement of sensitivity of human squamous carcinoma cells to radiation by epidermal growth factor. *J Natl Cancer Inst* 81(13):1020–1024
31. Bonner JA, Mahile NJ, Folven BR, Christianson TJ, Spain K (1994) The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. *Int J Radiat Oncol Biol Phys* 29(2):243–247
32. Balaban N, Moni J, Shannon M, Dang L, Murphy E, Goldkorn T (1996) The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. *Biochim Biophys Acta* 1314(1-2):147–156
33. Sheridan MT, O'Dwyer T, Seymour CB, Mothersill CE (1997) Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. *Radiat Oncol Investig* 5(4):180–186. doi:[10.1002/\(SICI\)1520-6823\(1997\)5:4<180::AID-ROI3>3.0.CO;2-U](https://doi.org/10.1002/(SICI)1520-6823(1997)5:4<180::AID-ROI3>3.0.CO;2-U)
34. Milas L, Fan Z, Andratschke NH, Ang KK (2004) Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. *Int J Radiat Oncol Biol Phys* 58(3):966–971. doi:[10.1016/j.ijrobp.2003.08.035](https://doi.org/10.1016/j.ijrobp.2003.08.035)
35. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L (1999) Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. *Clin Cancer Res* 5(10):2884–2890
36. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. *Cancer Res* 62(24):7350–7356
37. Goldkorn T, Balaban N, Shannon M, Matsukuma K (1997) EGF receptor phosphorylation is affected by ionizing radiation. *Biochim Biophys Acta* 1358(3):289–299
38. Contessa JN, Hampton J, Lammering G, Mikkelsen RB, Dent P, Valerie K, Schmidt-Ullrich RK (2002) Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. *Oncogene* 21(25):4032–4041. doi:[10.1038/sj.onc.1205500](https://doi.org/10.1038/sj.onc.1205500)

39. Lammering G, Hewit TH, Hawkins WT, Contessa JN, Reardon DB, Lin PS, Valerie K, Dent P, Mikkelsen RB, Schmidt-Ullrich RK (2001) Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. *J Natl Cancer Inst* 93(12):921–929
40. Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. *Cancer Res* 59(8):1935–1940
41. Gan HK, Burgess AW, Clayton AH, Scott AM (2012) Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. *Cancer Res* 72(12):2924–2930. doi:[10.1158/0008-5472.CAN-11-3898](https://doi.org/10.1158/0008-5472.CAN-11-3898)
42. ClinicalTrials.gov [database on the Internet] (2000) National Library of Medicine (US). National Library of Medicine (US), Bethesda, MD. Available via National Library of Medicine (US). <http://clinicaltrials.gov/>. Accessed 1 Aug 2015
43. Hatanpaa KJ, Burma S, Zhao D, Habib AA (2010) Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. *Neoplasia* 12(9):675–684
44. Raben D, Helfrich B, Bunn PA Jr (2004) Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. *Int J Radiat Oncol Biol Phys* 59(2 Suppl):27–38. doi:[10.1016/j.ijrobp.2004.01.054](https://doi.org/10.1016/j.ijrobp.2004.01.054)
45. Rao GS, Murray S, Ethier SP (2000) Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. *Int J Radiat Oncol Biol Phys* 48(5):1519–1528
46. Krause M, Schutze C, Petersen C, Pimentel N, Hessel F, Harstrick A, Baumann M (2005) Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC. *Radiother Oncol* 74(2):109–115. doi:[10.1016/j.radonc.2004.10.011](https://doi.org/10.1016/j.radonc.2004.10.011)
47. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, Cullinan C (2003) EGFR blockade with ZD1839 (“Iressa”) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. *Int J Radiat Oncol Biol Phys* 55(3):713–723
48. Shintani S, Li C, Mihara M, Terakado N, Yano J, Nakashiro K, Hamakawa H (2003) Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. *Int J Cancer* 107(6):1030–1037. doi:[10.1002/ijc.11437](https://doi.org/10.1002/ijc.11437)
49. Cuneo KC, Nyati MK, Ray D, Lawrence TS (2015) EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection. *Pharmacol Ther*. doi:[10.1016/j.pharmthera.2015.07.002](https://doi.org/10.1016/j.pharmthera.2015.07.002)
50. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N Engl J Med* 354(6):567–578. doi:[10.1056/NEJMoa053422](https://doi.org/10.1056/NEJMoa053422)
51. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS (2014) Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. *J Clin Oncol* 32(27):2940–2950. doi:[10.1200/JCO.2013.53.5633](https://doi.org/10.1200/JCO.2013.53.5633)
52. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. *Lancet Oncol* 16(2):187–199. doi:[10.1016/S1470-2045\(14\)71207-0](https://doi.org/10.1016/S1470-2045(14)71207-0)
53. Riaz N, Sherman EJ, Fury M, Lee N (2013) Should cetuximab replace Cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer? *J Clin Oncol* 31(2):287–288. doi:[10.1200/JCO.2012.46.9049](https://doi.org/10.1200/JCO.2012.46.9049)

54. Elie C, Geay JF, Morcos M, Le Tourneau A, Girre V, Broet P, Marmey B, Chauvenet L, Audouin J, Pujade-Lauraine E, Camilleri-Broet S (2004) Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). *Br J Cancer* 91(3):470–475. doi:[10.1038/sj.bjc.6601961](https://doi.org/10.1038/sj.bjc.6601961)
55. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. *J Clin Oncol* 23(9):1803–1810. doi:[10.1200/JCO.2005.08.037](https://doi.org/10.1200/JCO.2005.08.037)
56. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. *Nat Med* 9(6):669–676. doi:[10.1038/nm0603-669](https://doi.org/10.1038/nm0603-669)
57. Goel HL, Mercurio AM (2013) VEGF targets the tumour cell. *Nat Rev Cancer* 13(12):871–882. doi:[10.1038/nrc3627](https://doi.org/10.1038/nrc3627)
58. Kabbinar F, Hurwitz H, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. *J Clin Oncol* 21(1):60–65
59. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. *Nat Rev Drug Discov* 3(5):391–400. doi:[10.1038/nrd1381](https://doi.org/10.1038/nrd1381)
60. O'Reilly MS (2006) Radiation combined with antiangiogenic and antivascular agents. *Semin Radiat Oncol* 16(1):45–50. doi:[10.1016/j.semradonc.2005.08.006](https://doi.org/10.1016/j.semradonc.2005.08.006)
61. Teicher BA, Dupuis N, Kusomoto T, Robinson MF, Liu F, Menon K, Coleman CN (1994) Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. *Radiat Oncol Investig* 2(6):269–276
62. Wachsberger PR, Lawrence YR, Liu Y, Daroczi B, Xu X, Dicker AP (2012) Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts. *Int J Radiat Oncol Biol Phys* 82(1):483–491. doi:[10.1016/j.ijrobp.2010.09.019](https://doi.org/10.1016/j.ijrobp.2010.09.019)
63. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR (1998) Combined effects of angiostatin and ionizing radiation in antitumour therapy. *Nature* 394(6690):287–291. doi:[10.1038/28412](https://doi.org/10.1038/28412)
64. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. *Cancer Res* 59(14):3374–3378
65. Wachsberger P, Burd R, Dicker AP (2003) Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. *Clin Cancer Res* 9(6):1957–1971
66. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD (2001) Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. *Cancer Res* 61(1):39–44
67. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. *Cancer Cell* 6(6):553–563. doi:[10.1016/j.ccr.2004.10.011](https://doi.org/10.1016/j.ccr.2004.10.011)
68. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. *Nat Med* 7(9):987–989. doi:[10.1038/nm0901-987](https://doi.org/10.1038/nm0901-987)
69. Searle EJ, Illidge TM, Stratford IJ (2014) Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy. *Clin Oncol (R Coll Radiol)* 26(5):266–276. doi:[10.1016/j.clon.2014.02.006](https://doi.org/10.1016/j.clon.2014.02.006)

70. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. *N Engl J Med* 370(8):699–708. doi:[10.1056/NEJMoa1308573](https://doi.org/10.1056/NEJMoa1308573)
71. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. *N Engl J Med* 370(8):709–722. doi:[10.1056/NEJMoa1308345](https://doi.org/10.1056/NEJMoa1308345)
72. Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. *Nat Clin Pract Oncol* 3(1):24–40. doi:[10.1038/ncponc0403](https://doi.org/10.1038/ncponc0403)
73. Dietrich J, Wang D, Batchelor TT (2009) Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. *Expert Opin Investig Drugs* 18(10):1549–1557. doi:[10.1517/13543780903183528](https://doi.org/10.1517/13543780903183528)
74. Holderfield MT, Hughes CC (2008) Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis. *Circ Res* 102(6):637–652. doi:[10.1161/CIRCRESAHA.107.167171](https://doi.org/10.1161/CIRCRESAHA.107.167171)
75. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. *Nat Rev Mol Cell Biol* 4(12):915–925. doi:[10.1038/nrm1261](https://doi.org/10.1038/nrm1261)
76. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM (1994) A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. *Cell* 77 (2):261–271
77. Bhardwaj V, Cascone T, Cortez MA, Amini A, Evans J, Komaki RU, Heymach JV, Welsh JW (2013) Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. *Cancer* 119(10):1768–1775. doi:[10.1002/cncr.27965](https://doi.org/10.1002/cncr.27965)
78. Sipeki S, Bander E, Buday L, Farkas G, Bacsy E, Ways DK, Farago A (1999) Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering. *Cell Signal* 11(12):885–890
79. Stoker M, Gherardi E, Perryman M, Gray J (1987) Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. *Nature* 327(6119):239–242. doi:[10.1038/327239a0](https://doi.org/10.1038/327239a0)
80. Rosen EM, Knesel J, Goldberg ID, Jin L, Bhargava M, Joseph A, Zitnik R, Wines J, Kelley M, Rockwell S (1994) Scatter factor modulates the metastatic phenotype of the EMT6 mouse mammary tumor. *Int J Cancer* 57(5):706–714
81. Sonnenberg E, Meyer D, Weidner KM, Birchmeier C (1993) Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. *J Cell Biol* 123(1):223–235
82. Santos OF, Barros EJ, Yang XM, Matsumoto K, Nakamura T, Park M, Nigam SK (1994) Involvement of hepatocyte growth factor in kidney development. *Dev Biol* 163(2):525–529. doi:[10.1006/dbio.1994.1169](https://doi.org/10.1006/dbio.1994.1169)
83. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR Jr, Gonzalez-Angulo AM (2012) cMET and phospho-cMET protein levels in breast cancers and survival outcomes. *Clin Cancer Res* 18(8):2269–2277. doi:[10.1158/1078-0432.CCR-11-2830](https://doi.org/10.1158/1078-0432.CCR-11-2830)
84. Moriyama T, Kataoka H, Koono M, Wakisaka S (1999) Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review). *Int J Mol Med* 3(5):531–536
85. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, Resau JH, Vande Woude GF (1997) Met and hepatocyte growth factor/scatter factor expression in human gliomas. *Cancer Res* 57(23):5391–5398
86. Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, Ferrara AM, Bagala C, Cassano A, Larocca LM, Barone C (2011) Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? *Clin Colorectal Cancer* 10(4):325–332. doi:[10.1016/j.clcc.2011.03.028](https://doi.org/10.1016/j.clcc.2011.03.028)

87. Cheng TL, Chang MY, Huang SY, Sheu CC, Kao EL, Cheng YJ, Chong IW (2005) Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer. *Chest* 128(3):1453–1460. doi:[10.1378/chest.128.3.1453](https://doi.org/10.1378/chest.128.3.1453)
88. Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R (2002) Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. *Clin Cancer Res* 8(2):620–627
89. Masuya D, Huang C, Liu D, Nakashima T, Kameyama K, Haba R, Ueno M, Yokomise H (2004) The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. *Br J Cancer* 90(8):1555–1562. doi:[10.1038/sj.bjc.6601718](https://doi.org/10.1038/sj.bjc.6601718)
90. Nakamura Y, Niki T, Goto A, Morikawa T, Miyazawa K, Nakajima J, Fukayama M (2007) c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. *Cancer Sci* 98(7):1006–1013. doi:[10.1111/j.1349-7006.2007.00493.x](https://doi.org/10.1111/j.1349-7006.2007.00493.x)
91. Liu Y, Li Q, Zhu L (2012) Expression of the hepatocyte growth factor and c-Met in colon cancer: correlation with clinicopathological features and overall survival. *Tumori* 98(1):105–112. doi:[10.1700/1053.11508](https://doi.org/10.1700/1053.11508)
92. Fan S, Wang JA, Yuan RQ, Rockwell S, Andres J, Zlatapolskiy A, Goldberg ID, Rosen EM (1998) Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. *Oncogene* 17(2):131–141. doi:[10.1038/sj.onc.1201943](https://doi.org/10.1038/sj.onc.1201943)
93. Fan S, Ma YX, Wang JA, Yuan RQ, Meng Q, Cao Y, Laterra JJ, Goldberg ID, Rosen EM (2000) The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidylinositol 3' kinase. *Oncogene* 19(18):2212–2223. doi:[10.1038/sj.onc.1203566](https://doi.org/10.1038/sj.onc.1203566)
94. Aebersold DM, Kollar A, Beer KT, Laissue J, Greiner RH, Djonov V (2001) Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. *Int J Cancer* 96(1):41–54
95. De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T, Gabriele P, Comoglio PM, Boccaccio C (2011) Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. *J Natl Cancer Inst* 103(8):645–661. doi:[10.1093/jnci/djr093](https://doi.org/10.1093/jnci/djr093)
96. Qian LW, Mizumoto K, Inadome N, Nagai E, Sato N, Matsumoto K, Nakamura T, Tanaka M (2003) Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. *Int J Cancer* 104(5):542–549. doi:[10.1002/ijc.10997](https://doi.org/10.1002/ijc.10997)
97. Sheng-Hua C, Yan-Bin M, Zhi-An Z, Hong Z, Dong-Fu F, Zhi-Qiang L, Xian-Hou Y (2007) Radiation-enhanced hepatocyte growth factor secretion in malignant glioma cell lines. *Surg Neurol* 68(6):610–613. doi:[10.1016/j.surneu.2006.12.050](https://doi.org/10.1016/j.surneu.2006.12.050), discussion 613–614
98. Schweigerer L, Rave-Frank M, Schmidberger H, Hecht M (2005) Sublethal irradiation promotes invasiveness of neuroblastoma cells. *Biochem Biophys Res Commun* 330(3):982–988. doi:[10.1016/j.bbrc.2005.03.068](https://doi.org/10.1016/j.bbrc.2005.03.068)
99. Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B (2009) The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. *Radiat Oncol* 4:69. doi:[10.1186/1748-717X-4-69](https://doi.org/10.1186/1748-717X-4-69)
100. Medova M, Aebersold DM, Blank-Liss W, Streit B, Medo M, Aebi S, Zimmer Y (2010) MET inhibition results in DNA breaks and synergistically sensitizes tumor cells to DNA-damaging agents potentially by breaching a damage-induced checkpoint arrest. *Genes Cancer* 1(10):1053–1062. doi:[10.1177/1947601910388030](https://doi.org/10.1177/1947601910388030)
101. Yu H, Li X, Sun S, Gao X, Zhou D (2012) c-Met inhibitor SU11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation. *Biochem Biophys Res Commun* 427(3):659–665. doi:[10.1016/j.bbrc.2012.09.117](https://doi.org/10.1016/j.bbrc.2012.09.117)
102. Li B, Torossian A, Sun Y, Du R, Dicker AP, Lu B (2012) Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selec-

- tive c-Met inhibitor with radiosensitizing effects. *Int J Radiat Oncol Biol Phys* 84(4):e525–e531. doi:[10.1016/j.ijrobp.2012.06.025](https://doi.org/10.1016/j.ijrobp.2012.06.025)
103. Lin CI, Whang EE, Donner DB, Du J, Lorch J, He F, Jiang X, Price BD, Moore FD Jr, Ruan DT (2010) Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. *Mol Can Res* 8(9):1217–1226. doi:[10.1158/1541-7786.MCR-10-0162](https://doi.org/10.1158/1541-7786.MCR-10-0162)
104. Buchanan IM, Scott T, Tandle AT, Burgan WE, Burgess TL, Tofilon PJ, Camphausen K (2011) Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102. *J Cell Mol Med* 15(9):1999–2006. doi:[10.1111/j.1582-4934.2010.01122.x](https://doi.org/10.1111/j.1582-4934.2010.01122.x)
105. Lal B, Xia S, Abounader R, Laterra J (2005) Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. *Clin Cancer Res* 11(12):4479–4486. doi:[10.1158/1078-0432.CCR-05-0166](https://doi.org/10.1158/1078-0432.CCR-05-0166)
106. Peters S, Adjei AA (2012) MET: a promising anticancer therapeutic target. *Nat Rev Clin Oncol* 9(6):314–326. doi:[10.1038/nrclinonc.2012.71](https://doi.org/10.1038/nrclinonc.2012.71)
107. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A (1993) Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type I IGF receptor (Igf1r). *Cell* 75(1):59–72
108. Jacobs CI (2008) A review of the role of insulin-like growth factor 2 in malignancy and its potential as a modifier of radiation sensitivity. *Clin Oncol (R Coll Radiol)* 20(5):345–352. doi:[10.1016/j.clon.2008.02.004](https://doi.org/10.1016/j.clon.2008.02.004)
109. Samani AA, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. *Endocr Rev* 28(1):20–47. doi:[10.1210/er.2006-0001](https://doi.org/10.1210/er.2006-0001)
110. Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan L, Burgaud JL, Carter D, Baserga R, Glazer PM (1997) Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. *Cancer Res* 57(15):3079–3083
111. Riesterer O, Yang Q, Raju U, Torres M, Molkenkine D, Patel N, Valdecanas D, Milas L, Ang KK (2011) Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers. *Int J Radiat Oncol Biol Phys* 79(4):1179–1187. doi:[10.1016/j.ijrobp.2010.10.003](https://doi.org/10.1016/j.ijrobp.2010.10.003)
112. Allen GW, Saba C, Armstrong EA, Huang SM, Benavente S, Ludwig DL, Hicklin DJ, Harari PM (2007) Insulin-like growth factor-I receptor signaling blockade combined with radiation. *Cancer Res* 67(3):1155–1162. doi:[10.1158/0008-5472.CAN-06-2000](https://doi.org/10.1158/0008-5472.CAN-06-2000)
113. Chitnis MM, Lodhia KA, Aleksic T, Gao S, Protheroe AS, Macaulay VM (2014) IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination. *Oncogene* 33(45):5262–5273. doi:[10.1038/onc.2013.460](https://doi.org/10.1038/onc.2013.460)
114. Jin Q, Esteva FJ (2008) Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. *J Mammary Gland Biol Neoplasia* 13(4):485–498. doi:[10.1007/s10911-008-9107-3](https://doi.org/10.1007/s10911-008-9107-3)
115. Jones HE, Dutkowski CM, Barrow D, Harper ME, Wakeling AE, Nicholson RI (1997) New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145. *Int J Cancer* 71(6):1010–1018
116. Li P, Veldwijk MR, Zhang Q, Li ZB, Xu WC, Fu S (2013) Co-inhibition of epidermal growth factor receptor and insulin-like growth factor receptor 1 enhances radiosensitivity in human breast cancer cells. *BMC Cancer* 13:297. doi:[10.1186/1471-2407-13-297](https://doi.org/10.1186/1471-2407-13-297)
117. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 235(4785):177–182
118. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jager E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE (2012) Prognosis of metastatic gas-

- tric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. *Ann Oncol* 23(10):2656–2662. doi:[10.1093/annonc/mds104](https://doi.org/10.1093/annonc/mds104)
119. Hong TS, Wo JY, Kwak EL (2013) Targeted therapies with chemoradiation in esophageal cancer: development and future directions. *Semin Radiat Oncol* 23(1):31–37. doi:[10.1016/j.semradionc.2012.09.004](https://doi.org/10.1016/j.semradionc.2012.09.004)
 120. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ (1999) Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. *Cancer Res* 59(6):1347–1355
 121. Sambade MJ, Camp JT, Kimple RJ, Sartor CI, Shields JM (2009) Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. *Radiother Oncol* 93(3):639–644. doi:[10.1016/j.radonc.2009.09.006](https://doi.org/10.1016/j.radonc.2009.09.006)
 122. Kimple RJ, Vaseva AV, Cox AD, Baerman KM, Calvo BF, Tepper JE, Shields JM, Sartor CI (2010) Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. *Clin Cancer Res* 16(3):912–923. doi:[10.1158/1078-0432.CCR-09-1324](https://doi.org/10.1158/1078-0432.CCR-09-1324)
 123. Sambade MJ, Kimple RJ, Camp JT, Peters E, Livasy CA, Sartor CI, Shields JM (2010) Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts. *Int J Radiat Oncol Biol Phys* 77(2):575–581. doi:[10.1016/j.ijrobp.2009.12.063](https://doi.org/10.1016/j.ijrobp.2009.12.063)
 124. Safran H, Dipetrillo T, Akerman P, Ng T, Evans D, Steinhoff M, Benton D, Purviance J, Goldstein L, Tantravahi U, Kennedy T (2007) Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. *Int J Radiat Oncol Biol Phys* 67(2):405–409. doi:[10.1016/j.ijrobp.2006.08.076](https://doi.org/10.1016/j.ijrobp.2006.08.076)
 125. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. *J Clin Oncol* 29(25):3366–3373. doi:[10.1200/JCO.2011.35.0868](https://doi.org/10.1200/JCO.2011.35.0868)
 126. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. *Nat Rev Cancer* 10(2):116–129. doi:[10.1038/nrc2780](https://doi.org/10.1038/nrc2780)
 127. Eswarakumar VP, Lax I, Schlessinger J (2005) Cellular signaling by fibroblast growth factor receptors. *Cytokine Growth Factor Rev* 16(2):139–149. doi:[10.1016/j.cytogfr.2005.01.001](https://doi.org/10.1016/j.cytogfr.2005.01.001)
 128. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. *Nat Genet* 23(1):18–20. doi:[10.1038/12615](https://doi.org/10.1038/12615)
 129. Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsens IB, Stefansson IM, Fennell T, Cibulskis K, Zody MC, Akslen LA, Gabriel S, Wong KK, Sellers WR, Meyerson M, Greulich H (2008) Drug-sensitive FGFR2 mutations in endometrial carcinoma. *Proc Natl Acad Sci U S A* 105(25):8713–8717. doi:[10.1073/pnas.0803379105](https://doi.org/10.1073/pnas.0803379105)
 130. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schottle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansen S, Rauh D, Baessmann I, Altmüller J, Wainer Z, Conron M, Wright G, Russell P, Solomon B, Brambilla E, Brambilla C, Lorimier P, Sollberg S, Brustugun OT, Engel-Riedel W, Ludwig C, Petersen I, Sanger J, Clement J, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, Cappuzzo F, Ligorio C, Damiani S, Hallek M, Beroukhim R, Pao W, Klebl B, Baumann M, Buettner R, Ernestus K, Stoelben E, Wolf J, Nurnberg P, Perner S, Thomas RK (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. *Sci Transl Med* 2(62):62ra93. doi:[10.1126/scitranslmed.3001451](https://doi.org/10.1126/scitranslmed.3001451)

131. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM (1996) Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. *Nat Genet* 12(4):390–397. doi:[10.1038/ng0496-390](https://doi.org/10.1038/ng0496-390)
132. Brooks AN, Kilgour E, Smith PD (2012) Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. *Clin Cancer Res* 18(7):1855–1862. doi:[10.1158/1078-0432.CCR-11-0699](https://doi.org/10.1158/1078-0432.CCR-11-0699)
133. Cazet A, Charest J, Bennett DC, Sambrooks CL, Contessa JN (2014) Mannose phosphate isomerase regulates fibroblast growth factor receptor family signaling and glioma radiosensitivity. *PLoS One* 9(10), e110345. doi:[10.1371/journal.pone.0110345](https://doi.org/10.1371/journal.pone.0110345)
134. Fuks Z, Persaud RS, Alfieri A, McLoughlin M, Ehleiter D, Schwartz JL, Seddon AP, Cordon-Cardo C, Haimovitz-Friedman A (1994) Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. *Cancer Res* 54(10):2582–2590
135. Gu Q, Wang D, Wang X, Peng R, Liu J, Jiang T, Wang Z, Wang S, Deng H (2004) Basic fibroblast growth factor inhibits radiation-induced apoptosis of HUVECs. I. The PI3K/AKT pathway and induction of phosphorylation of BAD. *Radiat Res* 161(6):692–702
136. Ader I, Toulas C, Dalenc F, Delmas C, Bonnet J, Cohen-Jonathan E, Favre G (2002) RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death. *Oncogene* 21(39):5998–6006. doi:[10.1038/sj.onc.1205746](https://doi.org/10.1038/sj.onc.1205746)
137. Ader I, Delmas C, Skuli N, Bonnet J, Schaeffer P, Bono F, Cohen-Jonathan-Moyal E, Toulas C (2014) Preclinical evidence that SSR128129E--a novel small-molecule multi-fibroblast growth factor receptor blocker--radiosensitises human glioblastoma. *Eur J Cancer* 50(13):2351–2359. doi:[10.1016/j.ejca.2014.05.012](https://doi.org/10.1016/j.ejca.2014.05.012)
138. Hsu HW, Wall NR, Hsueh CT, Kim S, Ferris RL, Chen CS, Mirshahidi S (2014) Combination antiangiogenic therapy and radiation in head and neck cancers. *Oral Oncol* 50(1):19–26. doi:[10.1016/j.oraloncology.2013.10.003](https://doi.org/10.1016/j.oraloncology.2013.10.003)
139. Lopez-Chavez A, Carter CA, Giaccone G (2009) The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer. *Curr Opin Investig Drugs* 10(12):1305–1314
140. Bennett DC, Charest J, Sebolt K, Lehrman M, Rehemtulla A, Contessa JN (2013) High-throughput screening identifies aclinomycin as a radiosensitizer of EGFR-mutant non-small cell lung cancer. *Transl Oncol* 6(3):382–391
141. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Caveness WK, Rao PN, Beroukhi R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. *N Engl J Med* 353(19):2012–2024. doi:[10.1056/NEJMoa051918](https://doi.org/10.1056/NEJMoa051918)

Increasing the Therapeutic Ratio of Radiotherapy

Tofilon, P.J.; Camphausen, K. (Eds.)

2017, VIII, 280 p. 41 illus., 34 illus. in color., Hardcover

ISBN: 978-3-319-40852-1

A product of Humana Press